

Third Quarter Fiscal 2026 Results

February 5, 2026

Q3 Fiscal 2026 Conference Call Detail

Conference call will take place at **8:00 a.m. ET** on **February 5, 2026**, and can be accessed via live webcast: [Link](#) or teleconference: [Link](#).

The earnings release, accompanying slides and a replay of the conference call (beginning at 11:00 AM ET) are available online at www.haemonetics.com.

Conference call speakers:

Chris Simon
President & CEO

James D'Arecca
EVP, Chief Financial Officer

Olga Guyette
VP, Investor Relations & Treasury

Important Information

Safe Harbor for Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements do not relate strictly to historical or current facts and may be identified by the use of words such as “may,” “will,” “should,” “could,” “would,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “projects,” “predicts,” “forecasts,” “foresees,” “potential” and other words of similar meaning in conjunction with statements regarding, among other things, (i) plans and objectives of management for operations of Haemonetics Corporation (“Haemonetics” or the “Company”), including plans or objectives related to the Company’s strategy for growth; product development, commercialization and anticipated benefits; regulatory approvals; the impact of acquisitions and divestitures; market position and expenditures; and the Company’s market and regional alignment initiative; (ii) estimates or projections of future financial results, financial condition, capital expenditures, capital structure or other financial items, including with respect to the Company’s share repurchase program; and (iii) the assumptions underlying or relating to any statement described in points (i) and (ii) above. Such forward-looking statements are not meant to predict or guarantee actual results, performance, events or circumstances and may not be realized because they are based upon the Company’s current projections, plans, objectives, beliefs, expectations, estimates and assumptions and are subject to a number of risks and uncertainties and other influences. Actual results and the timing of certain events and circumstances may differ materially from those described by the forward-looking statements as a result of these risks and uncertainties.

Factors that may influence or contribute to the inaccuracy of the forward-looking statements or cause actual results to differ materially from expected or desired results can be found in the Company’s most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed or to be filed with the U.S. Securities Exchange Commission (the “SEC”) under the headings “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” and in the Company’s other periodic filings with the SEC. The Company does not undertake to update these forward-looking statements.

Non-GAAP Financial Measures

This presentation contains non-GAAP financial measures as defined under applicable SEC rules and regulations. These non-GAAP financial measures should be considered supplemental to, and not a substitute for, the Company’s reported financial results prepared in accordance with U.S. GAAP. We strongly encourage investors to review the Company’s financial statements and publicly-filed reports in their entirety and not rely on any single financial measure. Because non-GAAP financial measures are not standardized, it may not be possible to compare these financial measures to similarly titled measures used by other companies. To the extent available without unreasonable effort, we have provided reconciliations of these non-GAAP measures to their most comparable GAAP measure in the appendix to this presentation, which is available on our website at www.haemonetics.com. With the exception of fiscal 2026 revenue guidance, the Company does not provide a reconciliation of forward-looking non-GAAP measures because certain significant information necessary for such reconciliations are unavailable, dependent on future events outside of our control and cannot be predicted without unreasonable efforts.

When used in this presentation, organic revenue growth excludes the impact of currency fluctuation, acquisitions and divestitures. Organic ex-CSL revenue growth further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. Adjusted gross profit, adjusted operating income, adjusted provision for income taxes, adjusted net income and adjusted earnings per diluted share exclude restructuring costs, restructuring related costs, digital transformation costs, amortization of acquired intangible assets, asset impairments and write downs, amortization of fair value inventory step-up, costs related to compliance with the European Union Medical Device Regulation (“MDR”) and In Vitro Diagnostic Regulation (“IVDR”), acquisition, integration and divestiture related costs, net gains on the repurchase of convertible notes, gains on sales of property, plant and equipment, certain tax settlements, unusual or infrequent and material litigation-related charges, and remeasurement of contingent consideration. Adjusted net income and adjusted earnings per diluted share also exclude the tax impact of these items. The adjustments to provision for income taxes are calculated based on the jurisdictions in which pre-tax adjustments occurred. Free cash flow is defined as cash provided by operating activities less capital expenditures and additions to Haemonetics equipment, net of the proceeds from the sale of property, plant and equipment.

Use of Document

This presentation contains certain highlights with respect to our third quarter of fiscal 2026 performance and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our earnings release for the third quarter ended December 27, 2025 located in the investor relations section of our website at www.haemonetics.com and our Quarterly Report on Form 10-Q for the quarter ended December 27, 2025 filed with the SEC.

Q3 Fiscal 2026 Highlights

Delivering earnings growth and margin expansion despite last year's portfolio transitions

- (3%) reported revenue decline; 1% organic¹ revenue growth; 8% organic ex-CSL² revenue growth.
- Gross margin up 420bps Y/Y to 59.7%; Adjusted gross margin up 250bps Y/Y to 60.2%.
- Operating margin of 19.9%, up 300bps Y/Y; Adjusted operating margin of 26.3%, up 60bps Y/Y.
- EPS of \$0.95, up 28% Y/Y; Adjusted EPS of \$1.31, up 10% Y/Y.

Translating earnings into cash


- Cash flow from operating activities increased 114% and free cash flow increased 151%.
- Free cash flow to adjusted net income conversion ratio reached 121% in Q3; 95% YTD and 110% TTM³.

Creating additional avenues for value creation

- Strengthened category leadership in Vascular Closure with the acquisition of Vivasure Medical in January 2026.
- Bought back ~360k shares of HAE common stock subsequent to quarter-end.

1) Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. 2) In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. 3) Trailing twelve months.

Q3 Fiscal 2026 Revenue by Business Unit



(in millions)	Q3 2026	Q3 2025	Reported growth	Organic growth	Organic growth, ex-CSL
Plasma	\$138.9	\$134.2	3.5%	2.8%	20.2%
Apheresis	\$56.6	\$55.4	2.1%	2.8%	2.8%
Whole Blood	—	\$15.0	(100.0%)	—	—
Blood Center	\$56.6	\$70.3	(19.6%)	2.8%	2.8%
IVT ²	\$56.1	\$63.3	(11.4%)	(11.6%)	(11.6%)
BMT ³	\$87.4	\$80.7	8.3%	7.6%	7.6%
Hospital	\$143.5	\$144.0	(0.3%)	(0.9%)	(0.9%)
Total Net Revenues	\$339.0	\$348.5	(2.7%)	1.2%	7.5%

1) Portfolio transitions include the divestiture of the Whole Blood product line, the exit of certain liquid solution products and fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. 2) Interventional Technologies. 3) Blood Management Technologies.

Q3 Fiscal 2026 Financial Review

GAAP Results:

	Q3 2026	Q3 2025	Y/Y
Gross Margin %	59.7%	55.5%	+420bps
Operating Margin %	19.9%	16.9%	+300bps
Net Income Margin %	13.2%	10.8%	+240bps
Income Tax Rate	25.4%	24.9%	+50bps
Earnings Per Share	\$0.95	\$0.74	28%

Non-GAAP Results:

	Q3 2026	Q3 2025	Y/Y
Adjusted Gross Margin %	60.2%	57.7%	+250bps
Adjusted Operating Margin %	26.3%	25.7%	+60bps
Adjusted Net Income Margin %	18.1%	17.3%	+80bps
Adjusted Income Tax Rate	24.9%	25.2%	-30bps
Adjusted Earnings Per Share	\$1.31	\$1.19	10%

Q3 Fiscal 2026 Segment Performance

Plasma	Q3 2026	Q3 2025	Y/Y
Revenue	\$138.9M	\$134.2M	3.5% reported; 20.2% organic ex-CSL
Adjusted Operating Margin % ¹	36.2%	35.6%	+60bps

Blood Center	Q3 2026	Q3 2025	Y/Y
Revenue	\$56.6M	\$70.3M	(19.6%) reported; 2.8% organic
Adjusted Operating Margin % ¹	23.0%	20.4%	+260bps

Hospital	Q3 2026	Q3 2025	Y/Y
Revenue	\$143.5M	\$144.0M	(0.3%) reported; (0.9%) organic
Adjusted Operating Margin % ¹	18.1%	19.0%	-90bps

1) Operating income by reportable segment excludes corporate and unallocated expenses for amortization of acquired intangible assets, acquisitions, integration and divestiture related costs, restructuring and restructuring related costs, digital transformation costs, certain other litigation-related charges, MDR & IVDR costs and gains on sale of property, plant and equipment. Total corporate and unallocated expenses were \$21.8M in Q3 FY'26 and \$30.4M in Q3 FY'25. Please refer to the reconciliation table in Appendix F of this presentation for more information.


Balance Sheet and Cash Flow Metrics

(in millions)	12/27/25	3/29/25
Cash & cash equivalents	\$363	\$307
Working capital	\$404	\$357
Total debt	\$1,225	\$1,225
Net debt ¹	\$861	\$918
Available credit ²	\$749	\$749
Gross leverage ratio ³	2.84	2.93
Net leverage ratio ³	2.37	2.53

Cash from operations

(in millions)

■ FCF ■ CapEx and Other⁴



Free cash flow to adjusted net income ratio

1) Net debt is calculated as total debt minus cash & cash equivalents. 2) Available borrowing capacity under the existing revolving credit facility minus any eligible letters of credit. 3) Gross and net leverage ratios per the terms set forth in the Company's existing credit agreement. 4) Includes capital expenditures, non-cash inventory transfers of Haemonetics equipment and proceeds from the sale of property, plant and equipment.

Full Year Fiscal 2026 Guidance

	Previous	February 2026
Revenue (Reported)	(1 – 4%)	(1 – 3%)
Organic growth ¹	(1) – 2%	0 – 2%
Organic growth, ex-CSL ²	7 – 10%	8 – 10%
Adjusted Operating Margin %	26 – 27%	26 – 27%
Adjusted EPS	\$4.80 – \$5.00	\$4.90 – \$5.00
Free cash flow	\$170M – \$210M	\$200M – \$220M

Revenue guidance by segment:

- Plasma: (2 – 4%) reported; 17 – 19% organic growth, ex-CSL.
- Blood Center: (16 – 18%) reported; 1 – 3% organic growth.
- Hospital: ~4% reported; ~4% organic growth.
- Free cash flow to adjusted net income conversion ratio is expected to be in excess of 80% for the full year fiscal 2026.
- \$300M in convertible notes due in March 2026 are expected to be settled at maturity via cash on hand and borrowings under the existing revolving credit facility.

1) Excludes the impacts of currency fluctuation, the divestiture of the Whole Blood product line as of its completion in January 2025 and the exit of certain liquid solution products. 2) In addition to the adjustments for organic revenue, further excludes the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Appendices

Appendix A: Reconciliation of GAAP to Organic and Organic ex-CSL Revenue Growth Rates

(\$ millions)	Q3 2026	Q3 2025	Reported growth	Currency impact	Acquisitions & Divestitures ¹	Organic growth	2025 CSL US Disposable Revenue ²	Organic growth, ex-CSL
Plasma	\$138.9	\$134.2	3.5%	0.7%	–	2.8%	(17.4%)	20.2%
Apheresis	\$56.6	\$55.4	2.1%	1.3%	(2.0%)	2.8%	–	2.8%
Whole Blood	–	\$15.0	(100.0%)	–	(100.0%)	–	–	-
Blood Center	\$56.6	\$70.3	(19.6%)	1.1%	(23.5%)	2.8%	–	2.8%
IVT ³	\$56.1	\$63.3	(11.4%)	0.2%	–	(11.6%)	–	(11.6%)
BMT ⁴	\$87.4	\$80.7	8.3%	0.7%	–	7.6%	–	7.6%
Hospital	\$143.5	\$144.0	(0.3%)	0.6%	–	(0.9%)	–	(0.9%)
Total Net Revenues	\$339.0	\$348.5	(2.7%)	0.8%	(4.7%)	1.2%	(6.3%)	7.5%

1) Reflects the impact in Blood Center of the divestiture of the Whole Blood product line as of its completion in January 2025 as well as the impact in Plasma of the exit of certain liquid solution products. 2) Reflects the impact in Plasma of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company. 3) Interventional Technologies includes Vascular Closure, Sensor Guided Technologies and Esophageal Protection product lines of the Hospital business unit. 4) Blood Management Technologies includes Hemostasis Management, Cell Salvage and Transfusion Management product lines of the Hospital business unit.

Appendix B: Reconciliation of GAAP to Organic and Organic ex-CSL Fiscal Year 2026 Revenue Guidance

	Plasma	Blood Center	Hospital	Total Company
Reported	(2 – 4%)	(16 – 18%)	~4%	(1 – 3%)
Currency impact	–	~1%	–	~1%
Acquisitions & Divestitures ¹	–	(19%)	–	(4%)
Organic	(2 – 4%)	1 – 3%	~4%	0 – 2%
CSL 2025 US Disposables revenue ²	21%	–	–	8%
Organic, ex-CSL	17 – 19%	1 – 3%	~4%	8 – 10%

1) Reflects adjustment in Blood Center to exclude the impact of the Company's divestiture of its Whole Blood product line in January 2025 and exit of certain liquid solution products. 2) Reflects adjustment to exclude the impact of fiscal 2025 disposable sales to CSL Plasma under its transitional U.S. supply agreement with the Company.

Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2026 Financial Results

(\$ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other expense	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	\$202.4	\$135.0	\$67.4	(\$7.4)	\$15.2	\$44.7	\$0.95
Amortization of acquired intangible assets	—	(\$10.9)	\$10.9	—	\$2.6	\$8.3	\$0.20
Amortization of fair value inventory step up	\$1.3	—	\$1.3	—	\$0.3	\$1.0	\$0.02
Integration and transaction costs	\$0.3	(\$1.4)	\$1.7	—	\$0.6	\$1.1	\$0.02
Restructuring costs	—	(\$1.5)	\$1.4	—	\$0.4	\$1.0	\$0.02
Restructuring related costs	—	—	—	—	—	—	—
Digital transformation costs	—	(\$6.1)	\$6.1	—	\$1.4	\$4.7	\$0.10
Write downs of certain assets	—	(\$0.8)	\$0.8	—	\$0.2	\$0.6	\$0.01
Litigation-related charges	—	\$1.3	(\$1.3)	—	(\$0.3)	(\$1.0)	(\$0.02)
Impairment of intangible assets	—	(\$0.7)	\$0.7	—	\$0.1	\$0.6	\$0.01
Discrete tax items	—	—	—	—	(\$0.2)	\$0.2	—
Adjusted	\$204.0	\$114.8	\$89.2	(\$7.4)	\$20.3	\$61.4	\$1.31
Adjusted, as a percentage of net revenues	60.2%	33.9%	26.3%			18.1%	

Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Fiscal 2025 Financial Results

(\$ millions)	Gross profit	Operating expenses	Operating income	Interest and other expense	Provision for income taxes	Net income	Earnings per diluted share
Reported	\$193.5	\$134.5	\$59.0	(\$9.1)	\$12.4	\$37.5	\$0.74
Amortization of acquired intangible assets	—	(\$12.2)	\$12.2	—	\$3.0	\$9.2	\$0.18
Amortization of fair value inventory step up	\$3.3	—	\$3.3	—	\$0.8	\$2.5	\$0.05
Integration and transaction costs	\$0.4	\$0.2	\$0.2	\$0.1	\$0.2	\$0.1	—
Restructuring costs	\$3.0	(\$0.5)	\$3.5	—	\$1.0	\$2.5	\$0.05
Restructuring related costs	\$0.6	(\$0.8)	\$1.5	—	\$0.3	\$1.1	\$0.02
Digital transformation costs	—	(\$4.6)	\$4.6	—	\$1.1	\$3.5	\$0.07
Write downs of certain assets	—	(\$4.0)	\$4.0	—	\$1.0	\$3.0	\$0.06
MDR and IVDR costs	—	(\$1.0)	\$1.0	—	\$0.2	\$0.8	\$0.02
Litigation-related charges	—	—	—	—	—	—	—
Discrete tax items	—	—	—	—	—	—	—
Adjusted	\$201.0	\$111.5	\$89.4	(\$9.0)	\$20.1	\$60.3	\$1.19
Adjusted, as a percentage of net revenues	57.7%	32.0%	25.7%			17.3%	

Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2026 Financial Results

(\$ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other income (expense)	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	\$589.4	\$409.6	\$179.8	(\$23.3)	\$39.0	\$117.5	\$2.46
Amortization of acquired intangible assets	—	(\$33.5)	\$33.5	—	\$8.3	\$25.2	\$0.55
Amortization of fair value inventory step up	\$5.8	—	\$5.8	—	\$1.4	\$4.4	\$0.09
Integration and transaction costs	\$2.6	(\$3.0)	\$5.7	\$2.0	\$2.1	\$5.6	\$0.12
Restructuring costs	(\$0.6)	(\$3.5)	\$2.9	—	\$0.8	\$2.1	\$0.04
Restructuring related costs	\$0.1	(\$0.1)	\$0.1	—	—	\$0.1	—
Digital transformation costs	—	(\$16.5)	\$16.5	—	\$4.0	\$12.6	\$0.26
Write downs of certain assets	—	(\$0.8)	\$0.8	—	\$0.2	\$0.6	\$0.01
Litigation-related charges	—	\$0.5	(\$0.5)	—	(\$0.1)	(\$0.4)	(\$0.01)
Impairment of intangible assets	—	(\$9.3)	\$9.3	—	\$2.3	\$7.0	\$0.15
Discrete tax items	—	—	—	—	(\$0.2)	\$0.2	—
Adjusted	\$597.3	\$343.3	\$254.0	(\$21.3)	\$57.7	\$175.0	\$3.67
Adjusted, as a percentage of net revenues	60.5%	34.8%	25.7%			17.7%	

Appendix C: Reconciliation of GAAP to Non-GAAP Q3 Year-to-Date Fiscal 2025 Financial Results

(\$ millions)	Gross profit	Operating expenses	Operating income (loss)	Interest and other income (expense)	Provision (benefit) for income taxes	Net income (loss)	Earnings per diluted share
Reported	\$555.9	\$405.4	\$150.5	(\$9.1)	\$31.6	\$109.7	\$2.14
Amortization of acquired intangible assets	—	(\$37.0)	\$37.0	—	\$9.2	\$27.8	\$0.54
Amortization of fair value inventory step up	\$12.3	—	\$12.3	—	\$3.0	\$9.3	\$0.18
Integration and transaction costs	\$0.8	(\$12.7)	\$13.4	\$0.1	\$1.1	\$12.4	\$0.24
Restructuring costs	\$11.2	(\$1.8)	\$12.9	—	\$3.2	\$9.8	\$0.19
Restructuring related costs	\$2.5	(\$3.0)	\$5.6	—	\$1.3	\$4.3	\$0.08
Digital transformation costs	—	(\$15.8)	\$15.8	—	\$3.8	\$12.1	\$0.24
Write downs of certain assets	—	(\$4.0)	\$4.0	—	\$1.0	\$3.0	\$0.06
MDR and IVDR costs	—	(\$3.1)	\$3.1	—	\$0.7	\$2.4	\$0.05
Litigation-related charges	—	(\$1.1)	\$1.1	—	\$0.3	\$0.8	\$0.02
Gain on repurchase of convertible notes, net	—	—	—	(\$12.6)	(\$3.1)	(\$9.5)	(\$0.19)
Gains on sales of property, plant and equipment	—	\$14.1	(\$14.1)	—	(\$3.4)	(\$10.7)	(\$0.21)
Impairment of intangible assets	—	(\$2.4)	\$2.4	—	\$0.6	\$1.8	\$0.04
Discrete tax items	—	—	—	—	\$3.1	(\$3.1)	(\$0.06)
Adjusted	\$582.7	\$338.7	\$244.0	(\$21.7)	\$52.4	\$169.9	\$3.32
Adjusted, as a percentage of net revenues	56.6%	32.9%	23.7%			16.5%	

Appendix D: Reconciliation of Cash Flows

(\$ millions)	Q3 2026	Q3 2025	FY 2026 YTD	FY 2025 YTD
Free Cash Flow Reconciliation				
Cash provided by operating activities	\$93.6	\$43.8	\$222.3	\$65.2
Capital expenditures	(\$6.3)	(\$8.5)	(\$15.1)	(\$23.6)
Additions to Haemonetics equipment	(\$13.4)	(\$5.9)	(\$42.6)	(\$12.6)
Proceeds from sale of property, plant and equipment	\$0.4	\$0.3	\$0.8	\$20.8
Free cash flow	\$74.2	\$29.6	\$165.4	\$49.7

Appendix E: Reconciliation of GAAP to Non-GAAP of TTM Financial Results¹

(\$ millions)	TTM 2026 Net income (loss)	TTM 2025 Net income (loss)
Reported	\$175.4	\$130.1
Amortization of acquired intangible assets	\$33.7	\$35.5
Amortization of fair value inventory step up	\$6.4	\$11.8
Acquisition, Integration, transaction and divestiture costs	\$8.6	\$17.0
Restructuring costs	\$2.8	\$14.4
Restructuring related costs	\$1.4	\$6.4
Digital transformation costs	\$16.0	\$15.8
Write downs of certain in-process intangible assets and PCS2 related charges	\$0.6	\$6.4
MDR and IVDR costs	\$1.3	\$3.1
Litigation-related charges	\$1.0	\$0.8
Gain on repurchase of convertible notes, net	—	(\$9.5)
Gains on sales of property, plant and equipment	—	(\$10.7)
Impairment of intangible assets	\$7.0	\$1.8
Remeasurement of contingent consideration	(\$20.3)	(\$2.2)
Gain on Divestiture	—	(\$1.5)
Discrete tax items	\$2.6	(\$3.1)
Adjusted	\$236.5	\$216.0
Adjusted, as a percentage of net revenues	17.9%	15.7%

(\$ millions)	TTM 2026	TTM 2025
Free Cash Flow Reconciliation		
Cash provided by operating activities	\$338.8	\$129.2
Capital expenditures	(\$30.8)	(\$29.7)
Additions to Haemonetics equipment	(\$51.1)	(\$16.3)
Proceeds from sale of property, plant and equipment	\$3.3	\$21.4
Free cash flow	\$260.3	\$104.6

1) Reflects non-GAAP adjustments for each of the four subsequent quarters ending December 27, 2025 and December 28, 2024, respectively.

Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (1 of 2)

	Q3 2026	Q3 2025
Net revenues:		
Plasma	\$138.9	\$134.2
Blood Center	\$56.6	\$70.3
Hospital	\$143.5	\$144.0
Total net revenues	\$339.0	\$348.5
Significant segment expenses and operating performance:		
Plasma		
Cost of goods sold	\$56.8	\$58.7
Selling, general and administrative	\$27.1	\$23.5
Research and development	\$4.8	\$4.3
Plasma operating income	\$50.2	\$47.7
Blood Center		
Cost of goods sold	\$29.1	\$40.2
Selling, general and administrative	\$13.5	\$14.3
Research and development	\$1.0	\$1.5
Blood Center operating income	\$13.0	\$14.3
Hospital		
Cost of goods sold	\$49.1	\$48.7
Selling, general and administrative	\$59.9	\$59.1
Research and development	\$8.5	\$8.8
Hospital operating income	\$25.9	\$27.4

Appendix F: Reconciliation of Segment Operating Income to the Total Company Net Income (2 of 2)

	Q3 2026	Q3 2025
Corporate and unallocated expenses		
Amortization of acquired assets	(\$12.3)	(\$15.6)
Integration and transaction costs	(\$1.7)	(\$0.2)
Restructuring and restructuring related costs	(\$1.5)	(\$5.0)
Digital transformation costs	(\$6.1)	(\$4.6)
Other ¹	(\$0.3)	(\$5.0)
Operating income	\$67.4	\$59.0
Interest and other expense, net	(\$7.4)	(\$9.1)
Income before provision for income taxes	\$60.0	\$49.9

1) Comprised of litigation-related charges, impairment of intangible assets, and the write downs of certain assets for the three months ended December 27, 2025. Comprised of MDR and IVDR costs, litigation-related charges, and the write downs of certain assets for the three months ended December 28, 2024.